Current partner codePEPTIDESDE
NCT01968187·Phase 2·INTERVENTIONAL

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Status

Completed

Phase

Phase 2

Enrollment

38

Locations

3

Results

Posted

Publications

1

Study summary

What the protocol is testing.

The purpose of this study is to evaluate the safety and effectiveness of intranasal FE 992097 in children and adults with Prader-Willi Syndrome.

Interventions

Treatment arms and agents.

DRUG

FE 992097

Each spray pump actuation delivered a 50 μL volume of solution that contained 1.6 mg carbetocin (FE 992097); each dose consisted of 3 spray pump actuations in each nostril that delivered a total of 9.6 mg carbetocin. Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days.

DRUG

Placebo

Each spray pump actuation delivered a 50 μL volume of sterile sodium chloride solution 0.9%; each dose consisted of 3 spray pump actuations in each nostril. Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days.

Timeline

From registration to results.

  1. First posted

    Oct 23, 2013

  2. Study start

    Jan 20, 2014

  3. Primary completion

    Jul 16, 2014

  4. Study completion

    Jul 16, 2014

  5. Results posted

    Mar 27, 2025

  6. Registry updated

    Mar 27, 2025

Outcomes

What the study measures.

Primary outcomes

Change From Baseline in Hyperphagia in Prader-Willi Syndrome (PWS) Questionnaires- Responsiveness (HPWSQ-R) Total Score at End-of-treatment (Day 15)

Time frame · From Day 1 (baseline) to Day 15

The HPWSQ-R is an 11-item questionnaire examining the psychological, developmental, and neurobiological correlates of hyperphagia in PWS. The items are classified into 3 domains; behavior, drive, and severity with each item rated on a five-point scale (1: not at all/none of the time/extremely easy to 5: extremely/all of the time/extremely hard). The questionnaire was completed by the parent/caregiver using a 1-week recall period. Total score was the sum of all the items in the three domains and ranged from 11 (no hyperphagia behaviors) to 55 (most severe hyperphagia behaviors). Change from baseline in HPWSQ-R Total Score at Day 15 is presented for this outcome measure.

Secondary outcomes

Clinical Global Impression- Improvement After Treatment (CGI-I) Score at End-of-treatment (Day 15)

Time frame · At Day 15

The Clinical Global Impression (CGI) scale consists of a 7-point clinician rating of illness severity (1 = normal, not at all ill, 7 = among the most extremely ill patients), at the beginning of the trial (baseline) - Clinical Global Impression-Severity Rating (CGI-S) and a 7-point clinician rating of improvement of patient condition (1=very much improved since baseline/initiation of treatment, 7=very much worse from baseline), during and at the end of the trial (Day 15) - CGI-I. The CGI-I score at Day 15 is presented for this outcome measure.

Change From Baseline in HPWSQ-R Domain Scores (Behavior, Drive and Severity) at End-of-treatment (Day 15)

Time frame · From Day 1 (baseline) to Day 15

The HPWSQ-R is an 11-item questionnaire examining the psychological, developmental, and neurobiological correlates of hyperphagia in PWS. The items were classified into 3 domains; behavior, drive, and severity with each item rated on a five-point score range from 1 (not at all/none of the time/extremely easy) to 5 (extremely/all of the time/extremely hard). The questionnaire was completed by the parent/caregiver using a 1-week recall period. Changes in the HPWSQ-R Total Score and in the Domain Scores (behavior, drive, and severity) at Day 15 is presented for this outcome measure. HPWSQ-R Behavior, Drive and Severity scores range from 5-25, 4-20, and 2-10, respectively, with higher scores indicating a worse outcome. Change from baseline is presented = (Day 15 score minus Baseline score).

Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale Score (CY-BOCS) at End-of-treatment (Day 15)

Time frame · From Day 1 (baseline) to Day 15

The CY-BOCS is a clinician rated, semi-structured inventory of specific symptoms and symptom severity in pediatric obsessive-compulsive disorder (OCD). Total scores on the CY-BOCS are calculated using a symptom checklist and severity scale. The 10 severity items are summed to produce an Obsessions Severity Score (5 items), Compulsions Severity Score (5 items), and Total score (sum of all 10 severity items). The total score is calculated by summing the 10 individual scores and ranges from 0 (no obsessions or compulsions) to 40 (most severe OC).

Change From Baseline in the Food Domain Score of the Reiss Profile at End-of-treatment (Day 15)

Time frame · From Day 1 (baseline) to Day 15

The Food Domain Score of the Reiss Profile consisted of 7 questions that pertain to food seeking behavior. The questions were rated on a five point scale ranging from -2 (strongly disagree; this phrase is not at all characteristic of the person) to 2 (strongly agree; this phrase is definitely characteristic of the person). Total score was defined as the sum of all individual item scores. The total score ranged from -14 to 14 with higher scores indicating higher severity. Change from baseline in Food Domain of the Reiss Profile at Day 15 is presented for this outcome measure.

Eligibility

Who can take part.

Minimum age
10 Years
Maximum age
18 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Male or female 10-18 years of age (both inclusive) * Genetically confirmed diagnosis of Prader-Willi Syndrome * Determined to be in nutritional phase 3 Prader-Willi Syndrome based on Miller et al, 2011 Exclusion Criteria: * Known genetic, hormonal, or chromosomal cause of cognitive impairment other than Prader-Willi Syndrome * Presence of currently active psychotic symptoms * Presence of any cardiovascular disorders, epilepsy, frequent migraines or severe asthma * Previous diagnosis of autism spectrum disorder by a qualified healthcare provider * Prior or concomitant use of a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI), antipsychotic medication, wakefulness-promoting drug, or thyroid hormone unless dosage has been stable ≥6 months at time of screening

Study locations

3 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Florida University

Gainesville, Florida, United States

Winthrop University

Mineola, New York, United States

Vanderbilt University

Nashville, Tennessee, United States

Related trials

More studies on Carbetocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.